Current Faculty

	R. Rox Anderson
	Brett E. Bouma
	Apostolos G. Doukas
	Michael R. Hamblin
	Tayyaba Hasan
	Irene E. Kochevar
	Seemantini Nadkarni
	Charles P. Lin
	Robert W. Redmond
	Guillermo J. Tearney
	Hensin Tsao
	Benjamin Vakoc
	Robert H. Webb
	Mei X. Wu
	Anna Yaroslavsky
	Seok-Hyun (Andy) Yun

Visiting Faculty

Former Faculty

Research Staff

Administration

Publications by Hensin Tsao, M.D., Ph.D

2000

Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol. 2000 Sep;136(9):1118-22.

2001

Goggins WB, Finkelstein DM, Tsao H. Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer. 2001 Feb 15;91(4):874-80.

2002

Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo Z, Tsao H, De Luca M, Catricala C, O'Toole KM. A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 2002; 22(14):5157-5172.

Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA, Haluska FG. Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol 2002; 138(6):799-802.

2003

Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol 2003;139(12):1620-1624.

Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003; 97(3):639-643.

Tsao H, Mihm MC Jr, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and utaneous melanoma. J Am Acad Dermatol 2003; 49(5):865-872.

Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003; 139(3):282-288.

2004

Goggins W, Gao W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer 2004;111(5):792-4.

Tsai KY, Tsao H. The genetics of skin cancer. Am J Med Genet 2004;131C(1):82-92.

Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351(10):998-1012.

Tsao H, Feldman M, Fullerton JE, Sober AJ, Rosenthal D, Goggins W. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol 2004;140(1):67-70.

Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122(2):337-41.

Tsao H, Niendorf K. Genetic testing in hereditary melanoma. J Am Acad Dermatol 2004;51(5):803-8.

Tsao H, Sober AJ, Niendorf KB, Zembowicz A. Case 6-2004: a 48-year-old woman with multiple pigmented lesions and a personal and family history of melanoma. N Engl J Med 2004;350(9):924-32.

Yang G, Niendorf KB, Tsao H. A novel methionine-53-valine mutation of p16 in a hereditary melanoma kindred. J Invest Dermatol 2004;123(3):574-5.

2005

Somoano B, Niendorf KB, Tsao H. Hereditary cancer syndromes of the skin. Clin Dermatol 2005;23(1):85-106.

Yang G, Rajadurai A, Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol 2005;125:1242-51.

2006

Goggins W, Daniels GH, Tsao H. Elevation of thyroid cancer risk among cutaneous melanoma survivors. Int J Cancer. 2006 Jan 1;118(1):185-8.

Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D,Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E; Melanoma Genetics Consortium (GenoMEL). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006 Oct 15;66(20):9818-28.

Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006;12(7 Pt 2):2301s-2307s. [Review].

Niendorf KB, Goggins W, Yang G, Tsai KY, Shennan M, Bell DW, Sober AJ, Hogg D, Tsao H. MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J Med Genet. 2006 Jun;43(6):501-6.

Niendorf KB, Tsao H. Cutaneous melanoma: family screening and genetic testing. Dermatol Ther 2006 Jan-Feb;19(1):1-8.

Stratigos AJ, Yang G, Dimisianos R, Nicolaou V, Stefanaki I, Katsambas AD, Tsao H. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma. J Invest Dermatol. 2006 Feb;126(2):399-401.

Yang G, Zhang G, Pittelkow MR, Ramoni M, Tsao H. Expression Profiling of UVB Response in Melanocytes Identifies a Set of p53-Target Genes. J Invest Dermatol. 2006 Nov;126(11):2490-506.

2007

Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E,Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Cannon-Albright LA, Chaudru V,Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis N, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang JM, Leachman S, Mackie RM, Magnusson V, Mann G, Newton-Bishop J, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E, Study Group LM, Genomel MG. Features associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2007 Feb;44(2):99-106.

Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 2007 Feb 12;28(6):578-88.

Jarell AD, Lawrende D, Tsao H. The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. [Review]. Biologics: Targ Thera 2007;1(4):407-414.

Lang J, Hayward N, Goldgar D, Tsao H, Hogg D, Palmer J, Stark M, Tobias ES, MacKie R. The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry. Genes Chromosomes Cancer. 2007;46(3):277-87.

McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41.

Tsai KY, Tsao H. Primer on the human genome. J Amer Acad Derm 2007 May; 56(5):719-35.

Tsao H, Florez JC. Introduction to genetic association studies. [Editorial] JID 2007;127:2283-87.

Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122(2):337-41.

Tsao H, Tucker MA, Whitaker L, Yakobson E. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007 Feb;44(2):99-106.

Yang G, Curley D, Bosenberg MW, Tsao H. Loss of xeroderma pigmentosum C (xpc) enhances melanoma photocarcinogenesis in ink4a-arf-deficient mice. Cancer Res 2007;67(12):5649-57.

2008

Somoano B, Tsao H. Genodermatoses with cutaneous tumors and internal malignancies. Dermatol Clin. 2008;26(1):69-87.

Back to Faculty Bio